News

How glycoprotein GP38 from Crimean-Congo hemorrhagic fever virus could advance monoclonal antibody therapies
A recent study published in Science Translational Medicine involving scientists from the U.S. Army Medical Research Institute ...
News-Medical.Net on MSN2d
GP38 identified as key viral toxin and vaccine target in Crimean-Congo hemorrhagic fever virus research
A recent study published in Science Translational Medicine involving scientists from the U.S. Army Medical Research Institute of Infectious Diseases in collaboration with scientists from the Albert ...
GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent
Continues to Strengthen Its Pandemic Preparedness and Biodefense Vaccine Portfolio ATLANTA, GA - April 9, 2025 (NEWMEDIAWIRE) ...
Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), ...
EurekAlert!11d
MOPEVACLAS vaccine candidate for Lassa fever enters clinical trials
After more than 20 years of research on arenaviruses, an Institut Pasteur team led by Sylvain Baize has developed an original vaccine platform known as MOPEVAC, which will strengthen the Institut ...
PharmiWeb11d
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...